SCHEMBL10150332

SCHEMBL10150332

CCOC(=O)N1CCN(c2nc(-c3ccccc3O)nc3c2CC(C)CC3)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MAPT P10636 5/20 0.46
SMYD3 Q9H7B4 2/20 0.46
KMT2A Q03164 6/20 0.43
MEN1 O00255 5/20 0.43
ALDH1A1 P00352 3/20 0.42
USP2 O75604 1/20 0.42
HSD17B10 Q99714 1/20 0.42
KDM4E B2RXH2 2/20 0.42
LMNA P02545 1/20 0.42
POLB P06746 2/20 0.41
MAPK1 P28482 1/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41
GPR55 Q9Y2T6 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
ADRB2 P07550 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10150308 0.93 GAA (0.50) GAASMN1; SMN2MAPTSMYD3KMT2A
SCHEMBL10150352 0.84 GAA (0.47) GAASMN1; SMN2MAPTSMYD3KMT2A
SCHEMBL10150326 0.83 MEN1 (0.57) MAPTKMT2AMEN1ALDH1A1HSD17B10
SCHEMBL10150318 0.83 SMAD3 (0.53) MAPTKMT2AMEN1ALDH1A1USP2
SCHEMBL10150324 0.83 ALDH1A1 (0.53) MAPTKMT2AMEN1ALDH1A1USP2
SCHEMBL10150319 0.82 SMAD3 (0.52) MAPTKMT2AMEN1ALDH1A1USP2
SCHEMBL10150322 0.80 PIK3CA (0.52) SMN1; SMN2MAPTKMT2AMEN1ALDH1A1
SCHEMBL10150354 0.76 KMT2A (0.41) MAPTKMT2AMEN1ALDH1A1HSD17B10
SCHEMBL8299287 0.75 MEN1 (0.57) MAPTKMT2AMEN1ALDH1A1HSD17B10
SCHEMBL8297570 0.75 SMAD3 (0.53) MAPTKMT2AMEN1ALDH1A1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS, INC. (US) 2012-02-16 US disclosed
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS, INC. (US) 2012-02-16 US disclosed
US-7968545-B2 Compositions useful as inhibitors of voltage-gated ion channels VERTEX PHARMACEUTICALS INC. (US) 2011-06-28 US disclosed
US-7968545-B2 Compositions useful as inhibitors of voltage-gated ion channels VERTEX PHARMACEUTICALS INC. (US) 2011-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS KCNQ1, KCNN2, KCNH3 GAA 1215/4885SMN1; SMN2 662/4885MAPT 1627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.